Evidence map›Paper›PMID 19190167›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009

A two-stage case-control study of EGFR polymorphisms and breast cancer risk.

Young-Seoub Hong, Sandra L Deming, Yu-Tang Gao, Ji-Rong Long, Xiao-Ou Shu, Qiuyin Cai, Wei Lu, Wei Zheng

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The polymorphism of EGFR 142285G > A exerts no risk effect on breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Young-Seoub HongDepartment of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203-1738, USA.
Sandra L Deming
Yu-Tang Gao
Ji-Rong Long
Xiao-Ou Shu
Qiuyin Cai
Wei Lu
Wei Zheng

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Shanghai Breast Cancer StudyR01CA064277 · NCI · VANDERBILT UNIVERSITY · PI SHU, XIAO-OU · 1996 to 2012
$4.8M
MOLECULAR EPIDEMIOLOGIC STUDY OF BREAST CANCERR01CA090899 · NCI · VANDERBILT UNIVERSITY · PI ZHENG, WEI · 2000 to 2009
$3.5M
NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS R01 CA064277NCI NIH HHS R01 CA090899NCI NIH HHS R01 CA64277NCI NIH HHS R01 CA90899
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polymorphism, Single NucleotideBreast NeoplasmsCase-Control StudiesChinaChi-Square DistributionErbB ReceptorsFemaleGenotypeHaplotypesHumansIncidenceInterviews as TopicLogistic ModelsErbB Receptors

Identifiers

PMID19190167
PMCPMC2702716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.